publication date: Feb. 5, 2021

NCI Trials

NCI Trials for February 2021

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10355

A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies

Dana-Farber – Harvard Cancer Center LAO

Lee, Elizabeth Katherine

(617) 632-5269

 

Phase I – A051901

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Alliance for Clinical Trials in Oncology

Alencar, Alvaro Jose

(305) 243-4372

 

Phase II – EA3191

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

ECOG-ACRIN Cancer Research Group

Zandberg, Dan Paul

(412) 864-7955

 

Phase II – PEPN1924

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma

Pediatric Early Phase Clinical Trial Network

Reed, Damon Russell

(813) 745-3242

 

Phase III – ACNS1931

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Children’s Oncology Group

Bowers, Daniel Charles

(214) 648-3896

 

Phase Other – A152022

Alliance COVID-19 Pandemic Study

Alliance for Clinical Trials in Oncology

Hahn, Olwen Mary

(773) 702-4400

 

Phase Other – S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

SWOG

Shankaran, Veena

(206) 288-7456

 

Phase Pilot – PEPN21EHRPBTCN15

Pilot Study to Enable Electronic Laboratory Data Transfer Into Medidata Rave

Pediatric Early Phase Clinical Trial Network

Miller, Tamara Porter

(404) 727-9268

Copyright (c) 2021 The Cancer Letter Inc.